News|Articles|August 2, 2026

7 Dermatology Headlines You Missed in July 2026

Catch up on July dermatology news: vitiligo and alopecia data, a pipeline discontinuation, psoriasis comparisons, and an FDA sNDA acceptance.

July has been a busy month in dermatology, with new phase 3 data, a major pipeline setback, and fresh head-to-head comparisons reshaping the conversation around some of the field's most closely watched conditions.

Related to this article

October 30th, 2026

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism: RemIND data, bleeding counseling, and where it fits in practice

October 30th, 2026

Q&A: What Should Clinicians Ask Patients About Scalp Psoriasis and Hair Care?

Psoriasis advocates Nitika Chopra and Ayesha Patrick address common misconceptions, how patients can speak up, and simple tips for clinicians.

October 30th, 2026

ABCs in Dermatology: Rethinking JAK Inhibitor Safety in Atopic Dermatitis

Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, examine how ORAL Surveillance shaped JAK warnings and what long-term atopic dermatitis data show.

October 29th, 2026

Q&A: World Psoriasis Day—What Are Clinicians Missing in Skin of Color Care

On World Psoriasis Day, advocates Nitika Chopra and Ayesha Patrick discuss feeling dismissed and what dermatologists should know about skin of color care.

October 28th, 2026

ABCs in Dermatology: Topical PDE4 Inhibition in Atopic Dermatitis

Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, discuss where topical PDE4 inhibitors fit in atopic dermatitis and how to measure skin and itch response.

October 28th, 2026

The Medical Sisterhood: How to Approach Burnout, Boundaries, and Authenticity in Medicine

Shannon C. Trotter, DO, and Mona Shahriari, MD, discuss burnout, people-pleasing, public speaking, and the real life behind physicians’ polished personas.

October 27th, 2026

ORKA-001 Clears Skin in 61% of High-Dose Psoriasis Patients at Week 16

ORKA-001, a half-life extended IL-23p19 antibody, achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B psoriasis trial.

October 27th, 2026

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

This segment of Nguyen's 2026 Fall Clinical Dermatology interview highlights key insights on early dermatology career strategies and other information.